COCP Cocrystal Pharma, Inc.
Price Chart
Executive Summary
Cocrystal Pharma received FDA Fast Track designation for CDI-988, its oral antiviral candidate for norovirus treatment and prevention. This designation enables accelerated development, rolling NDA review, and more frequent FDA interactions, marking a significant regulatory milestone for the clinical-stage biotech.
Actionable Insight
The Fast Track designation meaningfully de-risks CDI-988's development path and could accelerate its timeline to market. Given COCP's $14M market cap, this represents a significant value inflection point. Traders should monitor upcoming clinical data from the Phase 1b study and future FDA interactions as potential catalysts.
Key Facts
- FDA granted Fast Track designation to CDI-988 for norovirus infection treatment and prophylaxis
- CDI-988 is the first oral antiviral candidate being developed for norovirus
- Fast Track status allows for rolling NDA review and more frequent FDA communication
- A Phase 1b norovirus challenge study is currently underway at Emory University School of Medicine
- Norovirus causes an estimated 685 million global cases annually with $60 billion in economic impact
Financial Impact
No direct financial impact disclosed, but Fast Track designation increases the probability of regulatory success and potential commercialization for CDI-988
Risk Factors
- CDI-988 is still in early-stage development with no guarantee of clinical success
- The company faces typical biotech risks including funding needs, clinical trial delays, and regulatory hurdles
- Market cap remains small at $14M, indicating high volatility and execution risk
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-014819 |
| Exhibit: ex99-1.htm | 0001493152-26-014819 |
| Document: 0001493152-26-014819-index-headers.html | 0001493152-26-014819 |
| Document: 0001493152-26-014819-index.html | 0001493152-26-014819 |
| Document: 0001493152-26-014819.txt | 0001493152-26-014819 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
4d ago
|
8-K
| $1.02 awaiting T+1 | awaiting T+1 | — | $0.9900 (−2.46%) |
|
Jun 3, 2026
10d ago
|
8-K
| $1.06 $1.05 | ▼ −0.94% | ▼ −1.34% | $0.9900 (−6.60%) |
|
May 27, 2026
16d ago
|
DEFA14A
| $1.13 $1.12 | ▼ −0.89% | ▼ −1.12% | $0.9900 (−12.39%) |
|
May 26, 2026
17d ago
|
8-K
| $1.13 $1.12 | ▼ −0.89% | ▼ −0.90% | $0.9900 (−12.39%) |
|
May 15, 2026
29d ago
|
Press Release
| $1.20 $1.18 | ▼ −1.67% | ▼ −1.60% | $0.9900 (−17.50%) |
|
May 4, 2026
5w ago
|
EFFECT
| $1.31 $1.38 | ▼ −5.34% | ▼ −4.55% | $0.9900 (+24.43%) |
|
Apr 2, 2026
10w ago
|
8-K
| $1.51 $1.50 | ▼ −0.66% | ▼ −1.14% | $0.9900 (−34.44%) |
|
Mar 31, 2026
10w ago
|
8-K
| $1.01 $1.02 | ▲ +0.99% | ▲ +0.24% | $0.9900 (−1.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access